ARGX Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of 25.88% compared to argenx SE's net margin of --. argenx SE's return on equity of 28.06% beat DBV Technologies SA's return on equity of -217.87%.

argenx SE has a consensus price target of $1,014.95, signalling upside risk potential of 36.8%. On the other hand DBV Technologies SA has an analysts' consensus of $39.89 which suggests that it could grow by 89.39%. Given that DBV Technologies SA has higher upside potential than argenx SE, analysts believe DBV Technologies SA is more attractive than argenx SE.

argenx SE has a beta of 0.458, which suggesting that the stock is 54.165% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.942, suggesting its less volatile than the S&P 500 by 194.186%.

argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

argenx SE quarterly revenues are $948M, which are larger than DBV Technologies SA quarterly revenues of --. argenx SE's net income of $245.4M is higher than DBV Technologies SA's net income of -$44.8M. Notably, argenx SE's price-to-earnings ratio is 38.31x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 11.89x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Mereo BioPharma Group Plc has a net margin of 25.88% compared to argenx SE's net margin of -2923.31%. argenx SE's return on equity of 28.06% beat Mereo BioPharma Group Plc's return on equity of -80.03%.

argenx SE has a consensus price target of $1,014.95, signalling upside risk potential of 36.8%. On the other hand Mereo BioPharma Group Plc has an analysts' consensus of $1.73 which suggests that it could grow by 446.71%. Given that Mereo BioPharma Group Plc has higher upside potential than argenx SE, analysts believe Mereo BioPharma Group Plc is more attractive than argenx SE.

argenx SE has a beta of 0.458, which suggesting that the stock is 54.165% less volatile than S&P 500. In comparison Mereo BioPharma Group Plc has a beta of 0.372, suggesting its less volatile than the S&P 500 by 62.788%.

argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. Mereo BioPharma Group Plc pays out -- of its earnings as a dividend.

argenx SE quarterly revenues are $948M, which are larger than Mereo BioPharma Group Plc quarterly revenues of --. argenx SE's net income of $245.4M is higher than Mereo BioPharma Group Plc's net income of -$7.3M. Notably, argenx SE's price-to-earnings ratio is 38.31x while Mereo BioPharma Group Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 11.89x versus 97.45x for Mereo BioPharma Group Plc. Usually stocks with elevated PS ratios are considered overvalued.

Koninklijke Philips NV has a net margin of 25.88% compared to argenx SE's net margin of 7.71%. argenx SE's return on equity of 28.06% beat Koninklijke Philips NV's return on equity of 7.99%.

argenx SE has a consensus price target of $1,014.95, signalling upside risk potential of 36.8%. On the other hand Koninklijke Philips NV has an analysts' consensus of $33.74 which suggests that it could grow by 25.93%. Given that argenx SE has higher upside potential than Koninklijke Philips NV, analysts believe argenx SE is more attractive than Koninklijke Philips NV.

argenx SE has a beta of 0.458, which suggesting that the stock is 54.165% less volatile than S&P 500. In comparison Koninklijke Philips NV has a beta of 0.814, suggesting its less volatile than the S&P 500 by 18.56%.

argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Koninklijke Philips NV offers a yield of 3.59% to investors and pays a quarterly dividend of $0.97 per share. argenx SE pays -- of its earnings as a dividend. Koninklijke Philips NV pays out 94.78% of its earnings as a dividend. Koninklijke Philips NV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

argenx SE quarterly revenues are $948M, which are smaller than Koninklijke Philips NV quarterly revenues of $5.9B. argenx SE's net income of $245.4M is lower than Koninklijke Philips NV's net income of $457.4M. Notably, argenx SE's price-to-earnings ratio is 38.31x while Koninklijke Philips NV's PE ratio is 25.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 11.89x versus 1.28x for Koninklijke Philips NV. Usually stocks with elevated PS ratios are considered overvalued.

uniQure NV has a net margin of 25.88% compared to argenx SE's net margin of -666.06%. argenx SE's return on equity of 28.06% beat uniQure NV's return on equity of -220.8%.

argenx SE has a consensus price target of $1,014.95, signalling upside risk potential of 36.8%. On the other hand uniQure NV has an analysts' consensus of $37.83 which suggests that it could grow by 120.44%. Given that uniQure NV has higher upside potential than argenx SE, analysts believe uniQure NV is more attractive than argenx SE.

argenx SE has a beta of 0.458, which suggesting that the stock is 54.165% less volatile than S&P 500. In comparison uniQure NV has a beta of 0.746, suggesting its less volatile than the S&P 500 by 25.425%.

argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend.

argenx SE quarterly revenues are $948M, which are larger than uniQure NV quarterly revenues of $5.6M. argenx SE's net income of $245.4M is higher than uniQure NV's net income of -$37.1M. Notably, argenx SE's price-to-earnings ratio is 38.31x while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 11.89x versus 61.83x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.